Details of Disease

General Information of Disease (ID: DISVKQ4X)

• Disease Name: Cardiac arrhythmias
• Synonyms: extrasystoles; cardiac arrhythmia; ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome; autosomal dominant cardiac arrhythmia (Kuhn); VACRDS
• Disease Class: BC9Z: Cardiac arrhythmia
• Disease Hierarchy:
  DISMT2VZ: Cardiogenetic disease
  DIS3HIWD: Autosomal dominant disease
  DIS1W8PP: Tachyarrhythmias
  DISVKQ4X: Cardiac arrhythmias
• ICD Code:
  ICD-11: ICD-11: BC9Z
  ICD-9: ICD-9: 427
  Expand ICD-11: 'BC9Z
  Expand ICD-10: 'I47.0; 'I49; 'I49.4; 'I49.8; 'I49.9; 'R00.0; 'R00.1
  Expand ICD-9: 427
• Disease Identifiers:
  MONDO ID: MONDO_0020745
  UMLS CUI: C5542154
  OMIM ID: 115000
  MedGen ID: 1781114

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aprindine	DMBXWU8	Approved	Small molecular drug	[1]
Practolol	DMGLZ26	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DIADENOSINE TETRAPHOSPHATE	DMTJOEL	Phase 2	Small molecular drug	[3]
IPAZILIDE FUMARATE	DMDJ91F	Phase 2	Small molecular drug	[4]
ROTIGAPTIDE	DMXB9RS	Phase 2	Small molecular drug	[5]
SELODENOSON	DMQM3IX	Phase 2	Small molecular drug	[6]
Cilobradine	DM7EAG8	Phase 1	Small molecular drug	[7]
Nibentan	DM8J3WE	Phase 1	Small molecular drug	[8]
UK-66914	DMO8Z1D	Phase 1	Small molecular drug	[9]

This Disease is Treated as An Indication in 18 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Almokalant	DMV3PEA	Discontinued in Phase 3	Small molecular drug	[10]
Tecadenoson	DM9T6MS	Discontinued in Phase 3	Small molecular drug	[11]
Ambasilide	DMA57O4	Discontinued in Phase 2	Small molecular drug	[12]
BRL-32872A	DMRKBIU	Discontinued in Phase 2	Small molecular drug	[13]
DRAFLAZINE	DMCZ75T	Discontinued in Phase 2	Small molecular drug	[14]
E-4031	DMU872N	Discontinued in Phase 2	Small molecular drug	[15]
E047/1	DMYTZMA	Discontinued in Phase 2	Small molecular drug	[16]
ENIPORIDE	DME7OCX	Discontinued in Phase 2	Small molecular drug	[17]
Levosemotiadil	DMKSY2R	Discontinued in Phase 2	Small molecular drug	[18]
MILACAINIDE TARTRATE	DMJLNUD	Discontinued in Phase 2	NA	[19]
MK-499	DMVEGW6	Discontinued in Phase 2	Small molecular drug	[20]
Org-7797	DMU5PFD	Discontinued in Phase 2	Small molecular drug	[21]
SOLPECAINOL HYDROCHLORIDE	DMHITR4	Discontinued in Phase 2	Small molecular drug	[22]
Artilide	DMJDYBX	Discontinued in Phase 1	Small molecular drug	[23]
SR-47063	DMAICVN	Discontinued in Phase 1	Small molecular drug	[24]
L-702958	DMO7GWC	Terminated	Small molecular drug	[25]
TERIKALANT	DM2X5R6	Terminated	Small molecular drug	[26]
TULOPAFANT	DMASENP	Terminated	Small molecular drug	[27]

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
G-256	DMVSJ92	Investigative	Small molecular drug	[28]
Trecetilide fumarate	DME94KO	Investigative	Small molecular drug	[29]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring. J Clin Pharm Ther. 2005 Feb;30(1):5-12.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 555).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1732).
• [4] ClinicalTrials.gov (NCT02040298) Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT00137332) Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT00040001) Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation. U.S. National Institutes of Health.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2355).
• [8] Electrophysiologic effects of nibentan (HE-11) on canine cardiac tissue. J Pharmacol Exp Ther. 1997 Mar;280(3):1137-46.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000131)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001219)
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5592).
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001764)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000403)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4590).
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2605).
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004632)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010029)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005516)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001597)
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2607).
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000279)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003158)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002256)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002328)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002728)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001820)
• [27] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001254)
• [28] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [29] IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23.